SVV-001 is unique among members of the Picornaviradae family in that transgenes can be inserted into the SVV-001 genome and expressed specifically within the tumor.  Transgenes can code for proteins to provide additional safety over non-specific treatments.  Transgenes coding for immune-modulatory elements further enhance the anti-cancer immune response. Transgenes that code for proteins can eliminate negatively modulate elements within the tumor that suppress the anti-tumor response.  Versions of SVV-001 are also being constructed to encode tumor antigens.

CLINICAL TRIALs

Our first product, SVV-001 , is in a clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, a top medical research center.

In this Phase I trial, SVV-001 will be administrated in combination with immunotherapy drugs called checkpoint inhibitors (nivolumab and ipilimumab) to test the tolerability, dosage and frequency of intratumoral therapy in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated high-grade (Grade 3) neuroendocrine tumors.

• Enrollment Status: Recruiting

• Research Partner: Sylvester Comprehensive Cancer Center

• ClinicalTrials.gov Identifier: NCT06889493

Pre-clinical studies

armed viruses

Armed SVV with immuno modulator transgenes are currently being developed to target many difficult-to-treat solid tumor cancer indications. Some of our armed viruses are in the discovery and pre-clinical development stage.

neutralizing antibody evasion

Our program aims to develop complimentary approaches to evade neutralizing antibodies that will enable successful multiple intravenous administrations of SVV-001.

BIOMARKERs

STI has developed a companion diagnostic for the infection of SVV. This companion diagnostic covers 8 different genes and allows to predict with 88% precision that a cell line or tumor is sensitive to SVV-001 infection, and has a 92% probability of assigning a sensitive cell line accurately.